ConductScience.org, home

Paper7533451

Effect of demographic factors, urinary peak flow rates, and Boyarsky symptom scores on patient treatment choice in benign prostatic hyperplasia.

Kaplan SA and 4 others. Urology, 1995. Cited by 31 papers, by iCite.

Cite this record

ConductScience Library. Effect of demographic factors, urinary peak flow rates, and Boyarsky symptom scores on patient treatment choice in benign prostatic hyperplasia. Papers, record 7533451. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/7533451

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Effect of demographic factors, urinary peak flow rates, and Boyarsky symptom scores on patient treatment choice in benign prostatic hyperplasia.
PubMed
Journal
Urology
PubMed
Year
1995
PubMed
Publication types
Clinical Trial, Journal Article
PubMed
Citations, by iCite
31
iCite
Relative citation ratio, by iCite
1.69
iCite
Revised in PubMed
2021-12-03
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Kaplan SAS A
2Goluboff ETE T
3Olsson CAC A
4Deverka PAP A
5Chmiel JJJ J

Source PubMed

Download CSV of authors

Topics14

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Prostatic HyperplasiaMajor topic
Adult
Age Factors
Aged
Aged, 80 and over
Follow-Up Studies
Humans
Male
Middle Aged
Prospective Studies
Racial Groups
Severity of Illness Index
Single-Blind Method
Urodynamics

Source PubMed

Download CSV of topics

Cited by8

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 31 citations.

PMIDTitleJournalYearIn PapersSource
26847294Is Tamsulosin 0.2 mg Effective and Safe as a First-Line Treatment Compared with Other Alpha Blockers?: A Meta-Analysis and a Moderator Focused Study.Yonsei Med J2016https://conductscience.org/library/papers/26847294PubMed
17516689Efficacy of low-dose tamsulosin on lower urinary tract symptoms suggestive of benign prostatic hyperplasia : a nonblind multicentre korean study.Clin Drug Investig2004https://conductscience.org/library/papers/17516689PubMed
16986060Factors in Predicting Failure with Medical Therapy for BPH.Rev Urol2005https://conductscience.org/library/papers/16986060PubMed
16985889alpha-Blocker Therapy: Current Update.Rev Urol2005https://conductscience.org/library/papers/16985889PubMed
16175413Progression delay in men with mild symptoms of bladder outlet obstruction: a comparative study of phytotherapy and watchful waiting.World J Urol2005https://conductscience.org/library/papers/16175413PubMed
12882719Urethral stents in benign prostate hyperplasia.Curr Urol Rep2003https://conductscience.org/library/papers/12882719PubMed
12084322The clinical role of alpha-blockers in the treatment of benign prostatic hyperplasia.Curr Urol Rep2000https://conductscience.org/library/papers/12084322PubMed
9951948Alpha-adrenoceptor antagonists in the treatment of benign prostatic hyperplasia.Drugs1999https://conductscience.org/library/papers/9951948PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/7533451

GET https://conductscience.org/api/papers/v1/7533451/authors